

Fig.1

| gene | polymorphism | gene | polymorphism |
|---|-----------------------|--|---------------------|
| Angiotensin converting enzyme | I/D in intron 16 | Insulin receptor substrate-1 | 3494G→A (Gly972Arg) |
| Angiotensin II type I receptor | -535C→T | Interleukin-10 | -1082G→A |
| Angiotensinogen | -6G→A | | -819T→C |
| Apolipoprotein A1 | -75G→A | | -592A→C |
| | 83C→T | Interleukin-1α | -889C→T |
| Apolipoprotein B | I/D in signal peptide | Interleukin-1β | -511C→T |
| Apolipoprotein C-III | -482C→T | | 3953C→T |
| | -482C→T | Interleukin-6 | -634C→G |
| Apolipoprotein E | -1100C→T | | -174G→C |
| | -491A→T | LDL receptor related protein | -1887C→A |
| | -219G→T | | 766C→T |
| | 3932T→C (Cys112Arg) | Leptin | 280G→A (Asp9Asn) |
| | 4070C→T (Arg158Cys) | Lipoprotein lipase | 1127A→G (Asn291Ser) |
| Apolipoprotein (a) | 93C→T | | 47C→T (Ala16Val) |
| | 121G→A | Manganese superoxide dismutase | 173T→C (Ile58Thr) |
| | 11764A→C (Thr12Pro) | | -7G→A |
| | -477C→T | Matrix Gla protein | 7158A→G (Thr83Ala) |
| ATP-binding cassette transporter 1 | 1051G→A (Arg219Lys) | | -1607G→GG |
| | 664G→A (Val7Met) | Metalloproteinase-1 (collagenase) | -82A→G |
| | -55A→C | Metalloproteinase-12 (macrophage elastase) | 2756A→G (Asp919Gly) |
| Atrial natriuretic peptide | 46A→G (Arg16Gly) | Methylenetetrahydrofolate reductase | 677C→T (Ala222Val) |
| Atrial natriuretic peptide clearance receptor | 79C→G (Gln27Glu) | | -2518G→A |
| β2-adrenergic receptor | 491C→T (Thr164Ile) | Monocyte chemoattractant protein-1 | 242C→T (His72Tyr) |
| | 190T→C (Trp64Arg) | NADH/NADPH oxidase p22 phox | 1128T→C (Leu7Pro) |
| β3-adrenergic receptor | -854G→A | Neuropeptide Y | -107T→C |
| β-Fibrinogen | -455G→A | Paraoxonase | 172A→T (Met55Leu) |
| | 148C→T | | 584G→A (Gln192Arg) |
| | 8059G→A (Arg448Lys) | PECAM1 (CD31) | 1454C→G (Leu125Val) |
| CD14 receptor | -260C→T | | |

Fig.2

| | | | |
|------------------------------------|-------------------------|--|----------------------|
| Chemokine receptor 2 | 190G→A (Val64Ile) | PECAM1 (CD31) | 4428G→A (Ser563Asn) |
| Cholesterol ester transfer protein | 1061A→G (Ile405Val) | Peroxisome proliferator-activated receptor- α | 696C→G (Leu162Val) |
| | 1163A→G (Asp442Gly) | Peroxisome proliferator-activated receptor- γ 2 | 34C→G (Pro12Ala) |
| | 1200G→A (Arg451Gln) | | 344C→A (Pro115Gln) |
| Coagulation factor V | 1691G→A (Arg506Gln) | Plasminogen-activator inhibitor-1 | -668/4G→5G |
| Coagulation factor VII | 11496G→A (Arg353Glu) | Platelet-activating factor acetylhydrolase | 994G→T (Val279Phe) |
| Coagulation factor XII | 46C→T | Prothrombin | 20210G→A |
| Coagulation factor XIII A-subunit | 163G→T (Val134Leu) | P-selectin | 76666A→C (Thr715Pro) |
| Connexin 37 | 1019C→T (Pro319Ser) | Scavenger receptor-BI | 4G→A (Gly2Ser) |
| Endothelial nitric oxide synthase | -786T→C | Serotonin 2A receptor | 403G→A (Val135Ile) |
| | 894G→T (Glu298Asp) | Stromelysin-1 | 102T→C |
| | 5665G→T (Lys198Asn) | Thrombomodulin | -1171/5A→6A |
| Endothelin-1 | 98G→T | | -33G→A |
| E-selectin | 561A→C (Ser128Arg) | | -10GG→TA |
| | 1839C→T (Leu554Phe) | | 845G→A (Ala25Thr) |
| | 5775C→G (Arg213Gly) | Thrombopoietin | 2136C→T (Ala455Val) |
| Extracellular superoxide dismutase | 2445G→A (Ala54Thr) | Thrombospondin 1 | 5713A→G |
| Fatty acid-binding protein 2 | 84635G→A (Val249Ile) | Thrombospondin 4 | 2210A→G (Asn700Ser) |
| Fractalkine receptor | 807C→T | Tissue factor pathway inhibitor | 1186G→C (Ala387Pro) |
| Glycoprotein Ia | 873G→A | Transforming growth factor- β 1 | 874G→A (Val264Met) |
| | 1648A→G (Lys505Glu) | | -509C→T |
| | 1018C→T (Thr145Met) | | 869T→C (Leu10Pro) |
| Glycoprotein Ib α | 1565T→C (Leu33Pro) | Tumor necrosis factor- α | -863C→A |
| Glycoprotein IIIa | 97A→C (Lys121Gln) | | -850C→T |
| Glycoprotein PC-1 | 825C→T (splice variant) | | -308G→A |
| G-protein β 3 subunit | 845G→A (Cys282Tyr) | | -238G→A |
| Hemochromatosis-associated protein | -480C→T | | -1234C→T |
| Hepatic lipase | -250G→A | | -1051G→A |

Fig.3

| Gene | SNP | Labels | Primers (5'→3') | Cycles | Probes (5'→3') | Formamide |
|-----------------------------------|------------|---------------------------------|--|--------|---|-----------|
| Angiotensinogen | -6G→A | TxR FITC Biotin | CGGCAGCTTCTTCCX <u>CG</u> GGCAGCTTCTTCCX <u>TG</u> CACCCCTAGCTATAATAGG | 35 | AGCCACTGATGCX <u>CG</u> AGCCACTGATGCX <u>TG</u> | 30% |
| Apolipoprotein C-III | -482C→T | Biotin FITC | CGGAGCCACTGATGC <u>XCG</u> CGGAGCCACTGATGC <u>X<u>TG</u></u> | 35 | AGCCACTGATGCX <u>TG</u> | |
| Apolipoprotein E | 3932T→C | Biotin FITC TxR Biotin | TGTTGGAGTAAGGCACAGAA GGACATGGAGGACGT <u>XCG</u> GGACATGGAGGACGT <u>X<u>TG</u></u> | 40 | | |
| E-selectin | 561A→C | Biotin | CGGGTACTGCACAGGC ACATTACCGTGGCCAX <u>TG</u> CATTACCGTGGCCAX <u>GG</u> | 35 | CACCGTGGCCAX <u>TG</u> CAGGAT CACCGTGGCCAX <u>GG</u> CAGGAT | 45% |
| Fatty acid-binding protein 2 | 2445G→A | Biotin | AGCTGCCGTACCAATACATCC TCACAGTCAAAGAACATCAAGX <u>GC</u> ATTACAGTCAAAGAACATCAAGX <u>AC</u> | 40 | GAATCAAGX <u>G</u> C <u>T</u> TCGAAACATT GAATCAAGX <u>A</u> CT <u>T</u> TCGAAACATT | 37.5% |
| G-protein β3 subunit | 825C→T | Biotin FITC Biotin | AAAAAACAAACTTCAA <u>TG</u> TCGA TCTGGGCATCACGT <u>XCG</u> TCTGGGCATCACGT <u>X<u>TG</u></u> | 35 | | |
| Glycoprotein Ia | 1648A→G | FITC TxR Biotin | GAATAGTAGGGGGCACTGA GAGTCTACCTGTTACTATCAA <u>AA</u> GAGTCTACCTGTTACTATCAA <u>GA</u> | 40 | | |
| Glycoprotein Iba | 1018C→T | Biotin FITC TxR Biotin | ACCAGTACTAAAGCAA <u>AA</u> AAACT CCAGGGCTCCTGX <u>CG</u> CCCAGGGCTCCTGX <u>TG</u> | 40 | | |
| Paraoxonase | 584G→A | FITC TxR Biotin | TGAGCTTCCAGCTGGGTG ACCCAATACATCTCCAGG <u>AXCG</u> AACCCAAATACATCTCCAG <u>GXCT</u> | 35 | | |
| Plasminogen-activator inhibitor-1 | -668/4G→5G | Biotin | GAATGATATGTGCTGGGAC GGCACAGAGAGACTGTGGACACG GGCGCCTCCGATGATAACA | 35 | TGGACACGTGGGGAGTCAG TGGACACGT <u>GG</u> AGTCAGC | 45% |

10/524021

Fig.4

| | | | | |
|--|---------|-----------------------|--|----|
| Platelet-activating factor acetylhydrolase | 994G→T | FITC TxR Biotin | TTCCTTTGGGGAGAACXGT ATTCCTTTGGGGAGAACXGT TCTTACCTGAAATCTCTGATCTCA | 40 |
| Thrombomodulin | 2136C→T | FITC TxR Biotin | CCCGACTCGGCCCTTXCC CCCAGACTGGGGCTTXTC GTCACAGTCGGTGCCTAATG | 40 |
| Thrombopoietin | 5713A→G | FITC TxR Biotin | CGACATCAGCATTTGCTXAT CGACATCAGCATTTGCTXGT CTGCAGGGAAAGGGAGCTGT | 35 |
| Thrombospondin 4 | 1186G→C | FITC TxR Biotin | CGAGTTGGGAACGCCACXCT CGAGTTGGGAACGCCACXGT GGTCTGCACTGACATGATGAG | 35 |
| Tumor necrosis factor-α | -863C→A | FITC TxR Biotin | GCCCCCTGTCTTCGTTAACXGG ATGGCCCTGTCTTCGTTAACXGT CCAGGGCTATGGAAAGTCGAGTATC | 35 |

Fig.5

| Gene | SNP | Gene | SNP |
|--|---------|------------------------------------|-------------|
| Men | | Women | |
| Angiotensinogen | -6G→A | Apolipoprotein C-III | -482C→T |
| Apolipoprotein C-III | -482C→T | Apolipoprotein E | 3932T→C |
| Apolipoprotein C-III | 1100C→T | Apolipoprotein E | 4070C→T |
| Apolipoprotein E | -219G→T | ATP-binding cassette transporter 1 | 1051G→A |
| Apolipoprotein E | 4070C→T | CD14 receptor | -260C→T |
| Chemokine receptor 2 | 190G→A | Connexin 37 | 1019C→T |
| Connexin 37 | 1019C→T | E-selectin | 561A→C |
| Endothelial nitric oxide synthase | -786T→C | Endothelial nitric oxide synthase | -786T→C |
| G-protein β3 subunit | 825C→T | Endothelin-1 | 5665G→T |
| Glycoprotein Ia | 1648A→G | Fatty acid-binding protein 2 | 2445G→A |
| Interleukin-10 | -819T→C | Glycoprotein Ibα | 1018C→T |
| Interleukin-10 | -592A→C | Insulin receptor substrate-1 | 3494G→A |
| NADH/NADPH oxidase p22 phox | 242C→T | Interleukin-6 | -634C→G |
| Platelet-activating factor acetylhydrolase | 994G→T | Paraoxonase | 584G→A |
| Thrombomodulin | 2136C→T | Plasminogen-activator inhibitor-1 | -668/4G→5G |
| Thrombopoietin | 5713A→G | Stromelysin-1 | -1171/5A→6A |
| Thrombospondin 4 | 1186G→C | Tumor necrosis factor-α | -850C→T |
| Transforming growth factor-β1 | 869T→C | Tumor necrosis factor-α | -238G→A |
| Tumor necrosis factor-α | -863C→A | | |

Fig.6

| | Stent implantation (n = 710) | | | |
|--------------------------------------|------------------------------|-------------------------|----------------------------|-------------------------|
| | No restenosis (n = 525) | Restenosis (n = 385) | No restenosis (n = 527) | Restenosis (n = 183) |
| Age (years) | 58.5 ± 9.5 | 55.9 ± 9.6*1 | 56.8 ± 8.8 | 53.8 ± 9.9*2 |
| Body mass index (kg/m ²) | 24.0 ± 2.9 | 24.2 ± 2.8 | 24.0 ± 3.0 | 23.5 ± 2.9 |
| Smoking (%) | 77.0 | 81.3 | 88.4 | 94.5† |
| Hypertension (%) | 68.0 | 79.5*2 | 77.8 | 83.1 |
| Systolic BP (mmHg) | 147.5 ± 25.3 | 152.6 ± 26.4*4 | 149.1 ± 25.9 | 156.4 ± 24.4*4 |
| Diastolic BP (mmHg) | 80.9 ± 14.0 | 85.4 ± 17.1*1 | 82.7 ± 15.2 | 87.0 ± 17.3*4 |
| Diabetes mellitus (%) | 32.4 | 40.0*3 | 41.4 | 50.3*3 |
| Fasting blood sugar (g/dL) | 119.5 ± 54.5 | 123.5 ± 47.8 | 118.6 ± 43.7 | 125.1 ± 54.2 |
| Hypercholesterolemia (%) | 57.3 | 56.9 | 56.9 | 55.2 |
| Total cholesterol (mg/dL) | 208.9 ± 43.0 | 210.9 ± 45.0 | 210.7 ± 48.1 | 203.0 ± 47.1 |
| Triglycerides (mg/dL) | 158.5 ± 101.9 | 147.0 ± 93.6 | 152.1 ± 129.9 | 139.0 ± 75.3 |
| HDL-cholesterol (mg/dL) | 46.4 ± 13.1 | 44.3 ± 13.6 | 44.4 ± 12.2 | 44.3 ± 14.1 |
| Hyperuricemia (%) | 23.0 | 18.4 | 14.4 | 22.4*3 |
| Uric acid (mg/dL) | 6.0 ± 1.6 | 5.8 ± 1.6 | 5.8 ± 1.7 | 5.6 ± 1.4 |
| Coronary lesions | | | | |
| Right coronary artery (%) | 30.5 | 28.3 | 32.4 | 39.9 |
| Left anterior descending (%) | 45.1 | 48.6 | 52.8 | 45.4 |
| Left circumflex (%) | 24.4 | 23.1 | 14.8 | 14.8 |

Fig.7

| | POBA (n = 480) | | Stent implantation (n = 291) | |
|--------------------------------------|----------------------------|-------------------------|------------------------------|------------------------|
| | No restenosis (n = 286) | Restenosis (n = 194) | No restenosis (n = 204) | Restenosis (n = 87) |
| Age (years) | 63.1 ± 10.2 | 65.8 ± 7.7*1 | 63.2 ± 8.8 | 67.0 ± 9.8*1 |
| Body mass index (kg/m ²) | 23.7 ± 3.4 | 23.4 ± 3.1 | 23.9 ± 3.3 | 23.5 ± 2.6 |
| Smoking (%) | 15.4 | 24.7*2 | 32.4 | 20.7*2 |
| Hypertension (%) | 65.0 | 62.9 | 85.3 | 55.2*3 |
| Systolic BP (mmHg) | 149.4 ± 28.3 | 148.2 ± 27.5 | 148.4 ± 31.0 | 156.1 ± 28.7 |
| Diastolic BP (mmHg) | 79.0 ± 15.5 | 77.8 ± 15.6 | 78.9 ± 14.0 | 84.5 ± 14.6*2 |
| Diabetes mellitus (%) | 32.2 | 45.4*1 | 42.6 | 79.3*3 |
| Fasting blood sugar (g/dL) | 121.6 ± 53.4 | 141.3 ± 65.4*1 | 135.9 ± 72.0 | 152.3 ± 57.0*4 |
| Hypercholesterolemia (%) | 69.9 | 63.9 | 70.6 | 72.4 |
| Total cholesterol (mg/dL) | 211.7 ± 38.4 | 213.1 ± 44.5 | 219.1 ± 46.6 | 218.7 ± 40.2 |
| Triglycerides (mg/dL) | 127.8 ± 61.8 | 129.6 ± 73.0 | 134.2 ± 82.7 | 161.0 ± 119.2*2 |
| HDL-cholesterol (mg/dL) | 47.4 ± 13.4 | 46.8 ± 14.6 | 56.2 ± 17.4 | 54.4 ± 13.5 |
| Hyperuricemia (%) | 17.5 | 22.7 | 33.8 | 17.2*1 |
| Uric acid (mg/dL) | 4.6 ± 1.2 | 4.6 ± 1.5 | 4.9 ± 1.4 | 4.8 ± 1.3 |
| Coronary arteries | | | | |
| Right coronary (%) | 22.7 | 47.9*3 | 45.6 | 34.5 |
| Left anterior descending (%) | 41.6 | 41.8 | 39.7 | 55.2*2 |
| Left circumflex (%) | 35.7 | 10.3‡ | 14.7 | 10.3 |

Fig.8

| Gene | SNP | Dominant | | Recessive | | Additive | |
|--|---------|---------------|---------------|---------------|---------------|----------|-----------------|
| | | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) |
| POBA | | | | | | | |
| Glycoprotein Ia | 1684A→G | 0.7410 | | 0.0012 | 0.5 (0.3-0.8) | 0.7401 | |
| G-protein β3 subunit | 825C→T | 0.2916 | | 0.0033 | 1.6 (1.2-2.3) | 0.0119 | 1.6 (1.1-2.4) |
| Tumor necrosis factor-α | -863C→A | 0.0066 | 1.5 (1.1-2.1) | 0.8408 | | 0.0039 | 1.6 (1.2-2.3) |
| Apolipoprotein C-III | -482C→T | 0.0096 | 1.5 (1.1-2.1) | 0.1986 | | 0.0216 | 1.6 (1.1-2.4) |
| Apolipoprotein E | 3932T→C | 0.0101 | 1.6 (1.1-2.4) | 0.7705 | | 0.0103 | 1.7 (1.1-2.5) |
| Angiotensinogen | -6G→A | 0.0307 | 0.4 (0.2-0.9) | 0.4615 | | 0.0306 | 0.4 (0.17-0.90) |
| Stent implantation | | | | | | | |
| Tumor necrosis factor-α | -863C→A | 0.0415 | 1.5 (1.0-2.1) | 0.0142 | 2.0 (1.1-3.6) | 0.0082 | 2.2 (1.2-3.9) |
| Thrombomodulin | 2136C→T | 0.0143 | 1.6 (1.1-2.3) | 0.2937 | | 0.0241 | 1.6 (1.1-2.3) |
| Thrombospondin 4 | 1186G→C | 0.0229 | 1.7 (1.1-2.7) | | | 0.0229 | 1.7 (1.1-2.7) |
| Platelet-activating factor acetylhydrolase | 994G→T | 0.0475 | 1.5 (1.0-2.2) | 0.3905 | | 0.0666 | |
| Thrombopoietin | 5713A→G | 0.3159 | | 0.0499 | 1.5 (1.0-2.1) | 0.8858 | |

Fig.9

| Gene | SNP | Dominant | | Recessive | | Additive | |
|-----------------------------------|------------|---------------|---------------|---------------|---------------|----------|---------------|
| | | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) |
| POBA | | | | | | | |
| Fatty acid-binding protein 2 | 2445G→A | 0.0001 | 2.3 (1.5-3.6) | 0.0014 | 2.7 (1.5-4.9) | 0.0001 | 3.8 (2.0-7.4) |
| Plasminogen-activator inhibitor-1 | -668/4G→5G | 0.0091 | 1.8 (1.2-2.7) | 0.6798 | | 0.0030 | 2.0 (1.3-3.1) |
| Glycoprotein Ib α | 1018C→T | 0.0117 | 1.8 (1.1-2.8) | 0.7326 | | 0.0003 | 2.4 (1.5-3.9) |
| Paraoxonase | 584G→A | 0.0174 | 1.6 (1.1-2.4) | 0.0270 | 2.4 (1.1-5.1) | 0.0098 | 2.8 (1.3-6.2) |
| E-selectin | 561A→C | 0.0249 | 2.9 (1.2-7.7) | | | 0.0249 | 2.9 (1.2-7.7) |
| Apolipoprotein E | 3932T→C | 0.0462 | 1.7 (1.0-2.8) | 0.5308 | | 0.0691 | |
| Stent implantation | | | | | | | |
| Plasminogen-activator inhibitor-1 | -668/4G→5G | 0.0013 | 3.2 (1.6-6.5) | 0.6063 | | 0.0003 | 4.2 (2.0-9.3) |
| Paraoxonase | 584G→A | 0.0083 | 2.5 (1.3-4.9) | 0.4102 | | 0.0114 | 2.5 (1.2-5.0) |
| Glycoprotein Ib α | 1018C→T | 0.0187 | 2.6 (1.2-5.7) | | | 0.0187 | 2.6 (1.2-5.7) |
| Apolipoprotein E | 3932T→C | 0.0299 | 2.5 (1.1-5.9) | 0.8671 | | 0.0046 | 3.6 (1.5-8.7) |
| Apolipoprotein C-III | -482C→T | 0.0602 | | 0.0337 | 2.3 (1.1-5.0) | 0.7313 | |

Fig.10

| Gene | chromosomal locus | SNP | Genetic model | P | Odds ratio | 95% CI |
|--|-------------------|---------|-------------------|--------|------------|-----------|
| POBA | | | | | | |
| Apolipoprotein E | 19q13.2 | 3932T→C | CC + TC versus TT | 0.0035 | 1.80 | 1.21-2.66 |
| Glycoprotein Ia | 5q23-q31 | 1684A→G | GG versus AG + AA | 0.0162 | 0.57 | 0.37-0.90 |
| Tumor necrosis factor- α | 6p21.3 | -863C→A | AA + CA versus CC | 0.0075 | 1.54 | 1.12-2.11 |
| G-protein $\beta 3$ subunit | 12p13 | 825C→T | TT versus CT + CC | 0.0187 | 1.51 | 1.07-2.12 |
| Apolipoprotein C-III | 11q23 | -482C→T | TT + CT versus CC | 0.0236 | 1.44 | 1.05-1.98 |
| Angiotensinogen | 1q42-q43 | -6G→A | AA + GA versus GG | 0.4384 | 0.70 | 0.29-1.70 |
| Stent implantation | | | | | | |
| Thrombospondin 4 | 5q13 | 1186G→C | CC + GC versus GG | 0.0217 | 1.75 | 1.08-2.81 |
| Tumor necrosis factor- α | 6p21.3 | -863C→A | AA versus CA + CC | 0.1140 | 1.61 | 0.89-2.91 |
| Thrombomodulin | 20p11.2 | 2136C→T | TT + CT versus CC | 0.0767 | 1.42 | 0.96-2.08 |
| Thrombopoietin | 3q26.3-q27 | 5713A→G | GG versus AG + AA | 0.1266 | 1.36 | 0.92-2.02 |
| Platelet-activating factor acetylhydrolase | 6p21.2-p12 | 994G→T | TT + GT versus GG | 0.3460 | 1.22 | 0.81-1.84 |

Fig.11

| Gene | chromosomal locus | SNP | Genetic model | P | Odds ratio | 95% CI |
|-----------------------------------|-------------------|------------|----------------------------|--------|------------|------------|
| POBA | | | | | | |
| E-selectin | 1q23-q25 | 561A→C | CC + AC versus AA | 0.0227 | 3.54 | 1.19-10.52 |
| Fatty acid-binding protein 2 | 4q28-q31 | 2445G→A | AA + GA versus GG | 0.0002 | 2.42 | 1.52-3.85 |
| Glycoprotein Ib α | 22q11.2 | 1018C→T | TT + CT versus CC | 0.0111 | 1.86 | 1.15-3.02 |
| Plasminogen activator inhibitor-1 | 7q21.3-q22 | -668/4G→5G | 5G/5G + 4G/5G versus 4G/4G | 0.0475 | 1.62 | 1.01-2.60 |
| Paraoxonase | 7q21.3 | 584G→A | AA + GA versus GG | 0.0994 | 1.45 | 0.93-2.25 |
| Apolipoprotein E | 19q13.2 | 3932T→C | CC + TC versus TT | 0.5569 | 1.19 | 0.661-2.16 |
| Stent implantation | | | | | | |
| Plasminogen activator inhibitor-1 | 7q21.3-q22 | -668/4G→5G | 5G/5G + 4G/5G versus 4G/4G | 0.0006 | 3.88 | 1.78-8.45 |
| Apolipoprotein C-III | 11q23 | -482C→T | TT versus CT + CC | 0.0100 | 3.11 | 1.31-7.38 |
| Paraoxonase | 7q21.3 | 584G→A | AA + GA versus GG | 0.0116 | 2.67 | 1.24-5.72 |
| Glycoprotein Ib α | 22q11.2 | 1018C→T | TT + CT versus CC | 0.0754 | 2.23 | 0.92-5.42 |
| Apolipoprotein E | 19q13.2 | 3932T→C | CC + TC versus TT | 0.3174 | 1.64 | 0.62-4.35 |

10/524021

Fig.12

| Apolipoprotein E (0 = TT, 1 = CC) | Glycoprotein Ia (0 = AA + AG, 1 = GG) | Tumor necrosis factor- α (0 = CC, 1 = CA = AA) | G-protein $\beta\gamma$ subunit (0 = CC = CT, 1 = TT) | Apolipoprotein C-III (0 = CC, 1 = CT = TT) | Odds ratio |
|--------------------------------------|--|--|--|---|------------|
| 1 | 0 | 1 | 1 | 1 | 10.55 |
| 1 | 0 | 1 | 1 | 0 | 7.33 |
| 1 | 0 | 1 | 0 | 1 | 6.99 |
| 1 | 0 | 1 | 0 | 0 | 4.85 |
| 1 | 0 | 0 | 1 | 1 | 6.85 |
| 1 | 0 | 0 | 1 | 0 | 4.76 |
| 1 | 0 | 0 | 0 | 1 | 4.54 |
| 1 | 0 | 0 | 0 | 0 | 3.15 |
| 1 | 1 | 1 | 1 | 1 | 6.03 |
| 1 | 1 | 1 | 1 | 0 | 4.19 |
| 1 | 1 | 1 | 0 | 1 | 3.99 |
| 1 | 1 | 1 | 0 | 0 | 2.77 |
| 1 | 1 | 1 | 1 | 1 | 3.91 |
| 1 | 1 | 1 | 1 | 0 | 2.72 |
| 1 | 1 | 1 | 0 | 1 | 2.59 |
| 1 | 1 | 1 | 0 | 0 | 1.80 |
| 0 | 0 | 0 | 1 | 1 | 5.86 |
| 0 | 0 | 0 | 1 | 0 | 4.07 |
| 0 | 0 | 0 | 0 | 1 | 3.88 |
| 0 | 0 | 0 | 0 | 0 | 2.70 |
| 0 | 0 | 0 | 1 | 1 | 3.81 |
| 0 | 0 | 0 | 1 | 0 | 2.64 |
| 0 | 0 | 0 | 0 | 1 | 2.52 |
| 0 | 0 | 0 | 0 | 0 | 1.75 |
| 0 | 0 | 0 | 1 | 1 | 3.35 |
| 0 | 0 | 0 | 1 | 0 | 2.33 |
| 0 | 0 | 0 | 0 | 1 | 2.22 |
| 0 | 0 | 0 | 0 | 0 | 1.54 |
| 0 | 0 | 0 | 1 | 1 | 2.17 |
| 1 | 1 | 1 | 0 | 1 | 1.51 |
| 1 | 1 | 0 | 0 | 0 | 1.44 |
| 1 | 1 | 0 | 0 | 1 | 1.00 |
| 1 | 1 | 0 | 0 | 0 | |

Fig.13

| Thrombospondin 4 (0 = GG, 1 = GC = CC) | Tumor necrosis factor- α (0 = CC + CA, 1 = AA) | Thrombomodulin (0 = CC, 1 = CT = TT) | Thrombopoietin (0 = AA = AG, 1 = GG) | Platelet-activating factor acetylhydrolase (0 = GG, 1 = GT = TT) | Odds ratio |
|---|--|---|---|---|------------|
| 1 | 1 | 1 | 1 | 1 | 6.64 |
| 1 | 1 | 1 | 1 | 0 | 5.44 |
| 1 | 1 | 1 | 0 | 1 | 4.88 |
| 1 | 1 | 1 | 0 | 0 | 4.00 |
| 1 | 1 | 0 | 1 | 1 | 4.67 |
| 1 | 1 | 0 | 1 | 0 | 3.83 |
| 1 | 1 | 1 | 0 | 0 | 3.44 |
| 1 | 1 | 1 | 0 | 1 | 3.44 |
| 1 | 1 | 0 | 0 | 0 | 2.82 |
| 1 | 1 | 1 | 1 | 1 | 4.12 |
| 1 | 0 | 1 | 1 | 0 | 3.38 |
| 1 | 1 | 1 | 0 | 1 | 3.03 |
| 1 | 1 | 1 | 0 | 0 | 2.49 |
| 1 | 1 | 0 | 0 | 1 | 2.90 |
| 1 | 1 | 0 | 1 | 0 | 2.38 |
| 1 | 1 | 0 | 0 | 1 | 2.14 |
| 1 | 1 | 0 | 0 | 0 | 1.75 |
| 1 | 0 | 1 | 1 | 1 | 3.79 |
| 1 | 1 | 1 | 1 | 1 | 3.11 |
| 1 | 1 | 1 | 0 | 0 | 2.67 |
| 1 | 0 | 0 | 0 | 1 | 2.79 |
| 1 | 0 | 1 | 1 | 0 | 2.29 |
| 0 | 0 | 1 | 1 | 1 | 2.19 |
| 0 | 0 | 1 | 0 | 0 | 1.96 |
| 0 | 0 | 0 | 0 | 1 | 1.61 |
| 0 | 0 | 0 | 0 | 0 | 2.36 |
| 0 | 0 | 0 | 1 | 1 | 1.93 |
| 0 | 0 | 0 | 1 | 0 | 1.73 |
| 0 | 0 | 0 | 1 | 1 | 1.42 |
| 0 | 0 | 0 | 0 | 1 | 1.66 |
| 0 | 0 | 0 | 0 | 0 | 1.36 |
| 0 | 0 | 0 | 1 | 0 | 1.22 |
| 0 | 0 | 0 | 0 | 1 | 1.00 |
| 0 | 0 | 0 | 0 | 0 | 1.00 |

Fig.14

| E-selectin (0 = AA, 1 = AC = CC) | Fatty acid-binding protein 2 (0 = GG, 1 = GA + AA) | Glycoprotein Ib α (0 = CC, 1 = CT = TT) | Plasminogen activator inhibitor-1 (0 = 4G/4G, 1 = 4G/5G = 5G/5G) | Plasminogen activator inhibitor-1 (0 = 4G/4G, 1 = 4G/5G = 5G/5G) | Paraoxonase (0 = GG, 1 = GA = AA) | Odds ratio |
|-------------------------------------|---|---|---|---|--------------------------------------|------------|
| 1 | 1 | 1 | 1 | 1 | 1 | 37.43 |
| 1 | 1 | 1 | 1 | 1 | 0 | 25.81 |
| 1 | 1 | 1 | 0 | 0 | 1 | 23.10 |
| 1 | 1 | 1 | 0 | 0 | 0 | 15.93 |
| 1 | 1 | 0 | 1 | 1 | 1 | 20.12 |
| 1 | 1 | 0 | 1 | 0 | 0 | 13.88 |
| 1 | 1 | 0 | 0 | 0 | 1 | 12.42 |
| 1 | 1 | 0 | 0 | 0 | 0 | 8.57 |
| 1 | 0 | 1 | 1 | 1 | 1 | 15.47 |
| 1 | 0 | 0 | 1 | 1 | 0 | 10.67 |
| 1 | 1 | 0 | 1 | 0 | 1 | 9.55 |
| 1 | 1 | 0 | 1 | 0 | 0 | 6.58 |
| 1 | 1 | 0 | 0 | 1 | 1 | 8.32 |
| 1 | 1 | 0 | 0 | 1 | 0 | 5.74 |
| 1 | 1 | 0 | 0 | 0 | 1 | 5.13 |
| 1 | 1 | 0 | 0 | 0 | 0 | 3.54 |
| 0 | 1 | 1 | 1 | 1 | 1 | 10.57 |
| 0 | 0 | 0 | 1 | 1 | 0 | 7.29 |
| 0 | 0 | 0 | 1 | 0 | 1 | 6.53 |
| 0 | 0 | 0 | 1 | 0 | 0 | 4.50 |
| 0 | 0 | 0 | 0 | 1 | 1 | 5.69 |
| 0 | 0 | 0 | 0 | 1 | 0 | 3.92 |
| 0 | 0 | 0 | 0 | 0 | 1 | 3.51 |
| 0 | 0 | 0 | 0 | 0 | 0 | 2.42 |
| 0 | 0 | 0 | 0 | 1 | 1 | 4.37 |
| 0 | 0 | 0 | 1 | 1 | 0 | 3.01 |
| 0 | 0 | 0 | 1 | 0 | 1 | 2.70 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1.86 |
| 0 | 0 | 0 | 0 | 1 | 1 | 2.35 |
| 0 | 0 | 0 | 0 | 1 | 0 | 1.62 |
| 0 | 0 | 0 | 0 | 0 | 1 | 1.45 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1.00 |

Fig.15

| Plasminogen activator inhibitor-1 (0 = 4G/4G, 1 = 5G/5G) | Apolipoprotein C-III (0 = CC + CT, 1 = TT) | (0 = GG, 1 = GA = AA) | Glycoprotein lb α (0 = CC, 1 = CT = TT) | (0 = TT, 1 = TC = CC) | Apolipoprotein E (0 = CC, 1 = CT = TT) | Odds ratio |
|---|---|-----------------------|---|-----------------------|---|------------|
| 1 | 1 | 1 | 1 | 1 | 1 | 117.83 |
| 1 | 1 | 1 | 1 | 1 | 0 | 71.85 |
| 1 | 1 | 1 | 0 | 1 | 1 | 52.84 |
| 1 | 1 | 1 | 0 | 0 | 0 | 32.22 |
| 1 | 1 | 0 | 1 | 1 | 1 | 44.13 |
| 1 | 1 | 0 | 1 | 0 | 0 | 26.91 |
| 1 | 1 | 0 | 0 | 0 | 1 | 19.79 |
| 1 | 1 | 0 | 0 | 0 | 0 | 12.07 |
| 1 | 0 | 1 | 1 | 1 | 1 | 37.89 |
| 1 | 0 | 1 | 1 | 0 | 0 | 23.10 |
| 0 | 0 | 1 | 1 | 0 | 1 | 16.99 |
| 0 | 0 | 1 | 0 | 0 | 0 | 10.36 |
| 0 | 0 | 0 | 0 | 1 | 1 | 14.19 |
| 0 | 0 | 0 | 0 | 1 | 0 | 8.65 |
| 1 | 0 | 0 | 0 | 0 | 1 | 6.36 |
| 1 | 0 | 0 | 0 | 0 | 0 | 3.88 |
| 1 | 0 | 0 | 0 | 0 | 0 | 30.37 |
| 0 | 1 | 1 | 1 | 1 | 0 | 18.52 |
| 0 | 0 | 1 | 1 | 0 | 1 | 13.62 |
| 0 | 0 | 0 | 0 | 0 | 0 | 8.30 |
| 0 | 0 | 0 | 0 | 1 | 1 | 11.37 |
| 0 | 0 | 0 | 0 | 1 | 0 | 6.94 |
| 0 | 0 | 0 | 0 | 0 | 1 | 5.10 |
| 0 | 0 | 0 | 0 | 0 | 0 | 3.11 |
| 0 | 0 | 1 | 0 | 0 | 0 | 9.76 |
| 0 | 0 | 0 | 1 | 1 | 0 | 5.95 |
| 0 | 0 | 0 | 1 | 1 | 1 | 4.38 |
| 0 | 0 | 0 | 0 | 0 | 0 | 2.67 |
| 0 | 0 | 0 | 1 | 1 | 1 | 3.66 |
| 0 | 0 | 0 | 0 | 1 | 0 | 2.23 |
| 0 | 0 | 0 | 0 | 0 | 1 | 1.64 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1.00 |

Fig.16